GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
14 mars 2024 08h45 HE
|
GRI Bio, Inc.
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a...
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
15 mai 2023 07h00 HE
|
BioRestorative Therapies, Inc
--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 ...
Standard Lithium Receives Notice of Allowance for Final U.S. Patent Covering DLE Process for Recovering Lithium From Brines
29 déc. 2022 06h00 HE
|
Standard Lithium
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
Standard Lithium Receives Notice of Allowance for Final U.S. Patent Covering DLE Process for Recovering Lithium From Brines
29 déc. 2022 03h01 HE
|
Standard Lithium
VANCOUVER, British Columbia, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
07 nov. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Standard Lithium Announces Notice of Allowance for U.S. Patents Covering DLE Process for Recovering Lithium From Brines
01 nov. 2022 06h00 HE
|
Standard Lithium
VANCOUVER, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative pre-commercial...
Standard Lithium Announces Notice of Allowance for U.S. Patents Covering DLE Process for Recovering Lithium From Brines
01 nov. 2022 03h01 HE
|
Standard Lithium
VANCOUVER, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative pre-commercial...
Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)
28 juil. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first and only FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions NORTHBROOK, Ill., July ...
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis
10 mai 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of...
Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering JATENZO® (testosterone undecanoate)
28 avr. 2022 09h05 HE
|
Clarus Therapeutics Holdings, Inc.
JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions Upon issuance, this patent will be...